Policybanaoo.com No1 Insurance company in India

Call Us: +919620062500

(Mon - Friday)

Mail us for help:

support@policybanaoo.com

3C, Third Floor 24, Tanoshi Building,

Kasavanahalli , Bengaluru

pooja tomar

FDA Approves New Label for Opioid Use Disorder Drug

FDA Approves New Label for Opioid Use Disorder Drug

Feb. 25, 2025 — The FDA has approved a new treatment plan for a long-acting injection, making it easier for people with moderate to severe opioid use disorder (OUD) to start and keep up with their treatment. The FDA has approved an updated treatment protocol for a drug called Sublocade…Read More
Read more
Novel Blood Test Enables Early Pancreatic Cancer Detection

Novel Blood Test Enables Early Pancreatic Cancer Detection

TOPLINE: The new blood-based assay PAC-MANN-1 (protease activity–based cancer marker using magnetic nanosensor-1) identified pancreatic ductal adenocarcinoma (PDAC) across all stages with high specificity and sensitivity. The assay showed improved detection of early-stage cancer when combined with carbohydrate antigen 19-9 (CA 19-9). METHODOLOGY: CA 19-9, the only Food and Drug Administration–approved biomarker for PDAC…Read More
Read more
Reappointed WHO Europe Chief Shares Vision for Public Health

Reappointed WHO Europe Chief Shares Vision for Public Health

In an interview with Medscape Medical News, Hans Henri P. Kluge, who recently was reappointed the World Health Organization’s (WHO’s) regional director for Europe, reflected on the lessons he learned during his past mandate, outlined strategic priorities for the region, and discussed innovative approaches to strengthening healthcare systems…Read More
Read more
Paxlovid Shows No Benefit in Vaccinated Seniors, Study Shows

Paxlovid Shows No Benefit in Vaccinated Seniors, Study Shows

TOPLINE: Treatment with Paxlovid in older adults did not appear to make a difference in whether or not they were hospitalized because of COVID-19. METHODOLOGY: Over a 9-month time span starting in April 2022, researchers analyzed the hospital data of over 1.6 million Ontario residents aged 65 to 74 years…Read More
Read more
Rethinking Treatment-Resistant Depression: New Hope Ahead?

Rethinking Treatment-Resistant Depression: New Hope Ahead?

Treatment-resistant depression (TRD) remains a significant challenge for psychiatrists and family physicians alike, defying multiple standard treatments and complicating patient care. However, despite its clinical importance, a universally accepted definition is still lacking, making it difficult to determine its prevalence and adding uncertainty to treatment decisions…Read More
Read more